This study is currently recruiting participants.
Number
17-C-0027
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 4 Years Max Age: N/A
Referral Letter Required
No
Population Exclusion(s)
None
Keywords
Natural History; HCT; Natural History
Recruitment Keyword(s)
Condition(s)
Hematopoietic Stem Cell Transplantation; Tissue Donors
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Cancer Institute
People who have had an allogeneic hematopoietic stem cell transplant (HCT) have bone marrow or an immune system that is damaged. They get stem cells from a donor who is a relative. Researchers want to study stem cell donors and recipients to learn about the long-term effects of HCT. They want to learn how the stem cells change and how to improve their ability to fight cancer.
Objective:
To provide long-term follow-up care for people who underwent or will undergo HCT. To collect data, blood, and tissue samples to learn about late complications after HCT.
Eligibility:
Adults age 18 and older who will undergo HCT or underwent HCT and are surviving one year or more from the date of HCT. The stem cell donors for these recipients are also needed.
Design:
Recipients will have 1 visit each year. They will have a physical exam. They will answer questions about their medical history and health. They will receive screening and surveillance testing. They will complete brief questionnaires.
Recipients will have blood tests. They may have tissue biopsies or specimens (such as tissue in their cheek or skin or bone marrow biopsy).
Recipients will give their current address and phone number, and the same data for one or two other people, who can get in contact with them.
After the first visit at the clinic, some recipients may see a doctor close to home to get the necessary information and send it to NIH.
Donors will come to the clinic for 1 visit. They will answer questions about their medical history. Blood samples will be taken.
--Back to Top--
INCLUSION CRITERIA FOR PATIENT SUBJECTS: -Patients who underwent HCT for any indication (malignant or non-malignant) and are surviving one year or more from the date of HCT (patients may be at any time point after HCT as long as it is greater than or equal to 1 year) OR patients who will be undergoing HCT for any indication (malignant or non-malignant) on an ETIB protocol. Patients do not need to have been transplanted under an ETIB protocol. -Age greater than or equal to 4 years -Ability of patient or patient s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document -Patients will need to have a primary care physician that will provide continued comprehensive care throughout the patient s participation in the study. EXCLUSION CRITERIA FOR PATIENT SUBJECTS: -Patients with active disease relapse or new hematologic malignancy including post-transplant lymphoproliferative disorder (PTLD) are excluded from protocol enrollment. INCLUSION CRITERIA FOR DONOR SUBJECTS: -Related stem cell donors of patients meeting the above criteria as a donor of stem cells or leukocytes -Age greater than or equal to 4 years -Ability of patient or patient s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document INCLUSION CRITERIA FOR PARENTS COMPLETING SURVEYS: -Parents/guardians of minors enrolled on the study who have undergone HCT -Willingness to complete surveys about the minor that underwent HCT
-Patients who underwent HCT for any indication (malignant or non-malignant) and are surviving one year or more from the date of HCT (patients may be at any time point after HCT as long as it is greater than or equal to 1 year) OR patients who will be undergoing HCT for any indication (malignant or non-malignant) on an ETIB protocol. Patients do not need to have been transplanted under an ETIB protocol.
-Age greater than or equal to 4 years
-Ability of patient or patient s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
-Patients will need to have a primary care physician that will provide continued comprehensive care throughout the patient s participation in the study.
EXCLUSION CRITERIA FOR PATIENT SUBJECTS:
-Patients with active disease relapse or new hematologic malignancy including post-transplant lymphoproliferative disorder (PTLD) are excluded from protocol enrollment.
INCLUSION CRITERIA FOR DONOR SUBJECTS:
-Related stem cell donors of patients meeting the above criteria as a donor of stem cells or leukocytes
-Ability of patient or patient s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed
consent document
INCLUSION CRITERIA FOR PARENTS COMPLETING SURVEYS:
-Parents/guardians of minors enrolled on the study who have undergone HCT
-Willingness to complete surveys about the minor that underwent HCT
Principal Investigator
Referral Contact
For more information: